Search Results - "Mey, Ulrich"
-
1
Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation
Published in Hematological oncology (01-12-2017)“…BRAF mutations are present in a variety of cancers and cause constitutive activation of the Ras‐Raf–MEK‐ERK signaling pathway. In cutaneous malignant melanoma,…”
Get full text
Journal Article -
2
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab
Published in Blood (31-01-2019)“…Publisher's Note: There is a Blood Commentary on this article in this issue…”
Get full text
Journal Article -
3
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Published in Blood (25-07-2019)“…The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs…”
Get full text
Journal Article -
4
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Published in Haematologica (Roma) (01-03-2016)“…Downregulation of the unfolded protein response mediates proteasome inhibitor resistance in multiple myeloma. The Human Immunodeficieny Virus protease…”
Get full text
Journal Article -
5
Improved survival of older patients with multiple myeloma in the era of novel agents
Published in Hematological oncology (01-12-2016)“…Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within…”
Get full text
Journal Article -
6
Outcome of older myeloma patients in relationship to comorbidities and availability of second‐generation novel agents in a real‐life setting
Published in Hematological oncology (01-10-2022)“…Major improvements in outcome of older patients with multiple myeloma (MM) have been achieved with the introduction of novel agents. Their impact in real‐life…”
Get full text
Journal Article -
7
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Published in The lancet oncology (01-04-2017)“…Summary Background Advanced stage Hodgkin's lymphoma represents a heterogeneous group of patients with different risk profiles. Data suggests that interim PET…”
Get full text
Journal Article -
8
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care
Published in Supportive care in cancer (01-07-2011)“…Purpose In this prospective multi-centre observational cohort study, we investigated the effect of an intensified multidisciplinary pharmaceutical care…”
Get full text
Journal Article -
9
Multiple Myeloma: EHA‐ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow‐up
Published in HemaSphere (01-02-2021)Get full text
Journal Article -
10
Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study
Published in Journal of clinical oncology (20-05-2007)“…Rituximab has been shown to be active in follicular lymphoma (FL), both as monotherapy and in combination with chemotherapy. We conducted a randomized trial…”
Get full text
Journal Article -
11
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd‐line therapy for relapsed and refractory multiple myeloma – a phase II trial
Published in British journal of haematology (01-03-2017)“…Summary The combination of lenalidomide (Revlimid®, R) and dexamethasone (d) is a standard regimen for patients with relapsed/refractory multiple myeloma…”
Get full text
Journal Article -
12
Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Published in Cancer investigation (13-09-2016)“…This analysis reports on 72 patients with relapsed or refractory non-Hodgkin lymphoma who were treated with R-DHAP salvage chemotherapy regimen followed by…”
Get full text
Journal Article -
13
EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID‐19 Pandemic
Published in HemaSphere (01-02-2021)Get full text
Journal Article -
14
Diagnosis and treatment of follicular lymphoma: an update
Published in Swiss medical weekly (01-01-2018)“…Over the last few years, there have been many changes in the management of patients with follicular lymphoma, resulting in improvements in progression-free…”
Get full text
Journal Article -
15
Atypical BCR-ABL mRNA transcripts in adult Acute lymphoblastic leukemia
Published in Haematologica (Roma) (01-12-2007)“…From Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik III, Berlin, Germany (TB, SS, ET); Friedrich-Alexander-Universität,…”
Get full text
Journal Article -
16
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08
Published in BMC cancer (28-02-2020)“…High rates of venous thromboembolic events (VTEs), mainly in advanced disease, are reported for patients with cancer of the upper gastrointestinal tract…”
Get full text
Journal Article -
17
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2 nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial
Published in British journal of haematology (01-03-2017)“…The combination of lenalidomide (Revlimid , R) and dexamethasone (d) is a standard regimen for patients with relapsed/refractory multiple myeloma (rrMM). With…”
Get full text
Journal Article -
18
Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Published in Swiss medical weekly (03-04-2019)“…This update on plasma cell myeloma has been elaborated by a Swiss expert panel as a result of the plethora of new data on the treatment of plasma cell myeloma…”
Get full text
Journal Article -
19
Neutropenic enterocolitis in adults: systematic analysis of evidence quality
Published in European journal of haematology (01-07-2005)“…: Objective: Neutropenic enterocolitis is a life‐threatening complication occurring most frequently after intensive chemotherapy in acute leukaemias. The…”
Get full text
Journal Article -
20
Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10
Published in Blood (06-12-2014)“…Background: Previous trials from the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) showed that therapy with single-agent…”
Get full text
Journal Article